Key Statistics for SCLN
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (USD) (ttm)
|Est. EPS (USD) (12/2013)
|Est. PEG Ratio
|Market Cap (M USD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for SCLN
- Net Income (M/USD)
SciClone Pharmaceuticals, Inc. is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. The Company's products are for treating chronic and life-threatening diseases such as cancer, hepatitis B, hepatitis C, cystic fibrosis, and immune system disorders.
More Company Profile & Key Executives for SCLN
|Friedhelm BlobelPresident/CEO||Hong ZhaoCEO:China Operations|
|Gary S TitusSenior VP:Finance/CFO|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries